The Technical Analyst
Immune Therapeutics, Inc. [IMUN]
Exchange: PNK Industry: Biotechnology
Immune Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-7.00% $0.0930
America/New_York / 18 okt 2023 @ 12:27
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.78 mill |
| EPS: | 1.180 |
| P/E: | 0.0788 |
| Earnings Date: | N/A |
| SharesOutstanding: | 83.62 mill |
| Avg Daily Volume: | 0.0133 mill |
| RATING 2023-11-13 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0.0788 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 0.0788 | industry: PE -107.25 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0710 - 0.0890 ( +/- 11.25%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-02-10 | Farmer Glen A | Buy | 409 000 | Common Stock |
| 2022-07-25 | H. Louis Salomonsky Jr. Revocable Trust | Sell | 0 | Common Stock |
| 2022-07-25 | Salomonsky Henry Louis | Buy | 0 | Common Stock |
| 2022-07-25 | Salomonsky Henry Louis | Sell | 0 | Common Stock |
| 2022-08-02 | Farmer Glen A | Buy | 0 |
| INSIDER POWER |
|---|
| 100.00 |
| Last 55 transactions |
| Buy: 10 341 712 | Sell: 6 700 401 |
Forecast:
01:40 - $-0.0280
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0930 (-7.00% ) |
| Volume | 0.0018 mill |
| Avg. Vol. | 0.0133 mill |
| % of Avg. Vol | 13.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IMUN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IMUN
Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is headquartered in Orlando, Florida.
Latest Press Releases
2023-09-14 09:15:00 - Press Release
Biostax Corp Announces The Passing Of Esteemed Director, H. Louis Salomonsky
Orlando, fl, sept. 14, 2023 (globe newswire) -- immune therapeutics, inc. d/b/a biostax corp (otc pink: imun) (“biostax”), a hub and spoke biotech development engine, sadly announces the passing of h. louis salomonksy, a dedicated member of its board of directors. mr. salomonksy passed away on august 31, 2023, surrounded by family and loved ones.
2023-08-29 09:05:00 - Press Release
Biostax Corp. Signs Collaboration Agreement With Immgenuity, Inc. To Pursue Remission In Hiv
Orlando, fl, aug. 29, 2023 (globe newswire) -- immune therapeutics, inc. d/b/a biostax corp . (otc pink: imun) (“biostax”), a hub-and-spoke biotech development engine, announces the signing of a research collaboration agreement with immgenuity, inc . the joint research will focus on using immgenuity's imtv014 and biostax's lodonal™ and jkb-122 both independently and together to determine if the immune modulatory effects of biostax's drug therapies combined with immgenuity's imtv014 can achieve remission with hiv patients.
2023-08-15 09:05:00 - Press Release
Biostax Corp Announces The Fdas Acceptance Of Three Investigational New Drug Applications (ind) Transfers For Jkb-122 For The Treatment Of Nash, Nafld And Aih
Orlando, fl, aug. 15, 2023 (globe newswire) -- immune therapeutics, inc. d/b/a biostax corp. (otc pink: imun) ("biostax"), a hub-and-spoke biotech development engine, announces that they have accepted the transfer of three investigational new drug applications (ind) for the drug candidate, jkb-122 and the u.s. food and drug administration (fda) has finalized those transfers. the inds that were transferred to biostax include ind 146955 for the treatment of nonalcoholic steatohepatitis (nash) and fibrosis, ind 147347 for the treatment of nonalcoholic liver disease (nafld) and ind 127303 for the treatment of autoimmune hepatitis along with the orphan designation for autoimmune hepatitis. these inds were transferred from taiwanj pharmaceuticals, who licensed the development and commercialization of jkb-122 to biostax corp in 2022.
2021-06-04 12:22:00 - Press Release
Immune Therapeutics Announces Restructuring Plan
Orlando, florida , june 04, 2021 (globe newswire) -- immune therapeutics inc. (otc-pink: imun) (the "company") announced today that the company has received and signed a non-binding term sheet to enter into an agreement that would provide working capital and wipe out a significant portion of its long-standing debt.
2021-05-11 07:30:00 - Press Release
Immune Therapeutics Finra Approval For 1:1000 Reverse Stock Split
Orlando, florida , may 11, 2021 (globe newswire) -- immune therapeutics inc. (otc-pink: imun) (the "company") announced today that finra has processed a reverse split of 1-for 1,000 of the issued and outstanding stock. the reverse stock split was completed with the state of florida on march 12, 2020. finra's processing was the last step necessary to fully effectuate the reverse split approved by shareholders in october of 2019.
Latest News
2021-12-17 13:50:21 - InvestorPlace
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! The post The 10 Most Shorted Stocks Right Now for Friday, Dec. 17 appeared first on InvestorPlace.
2021-06-04 12:22:00 - GlobeNewsWire
Immune Therapeutics Announces Restructuring Plan
Orlando, Florida , June 04, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the "Company") announced today that the Company has received and signed a non-binding term sheet to enter into an agreement that would provide working capital and wipe out a significant portion of its long-standing Debt.
2021-05-11 07:30:00 - GlobeNewsWire
Immune Therapeutics FINRA Approval for 1:1000 Reverse Stock Split
Orlando, Florida , May 11, 2021 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTC-PINK: IMUN) (the "Company") announced today that FINRA has processed a reverse split of 1-for 1,000 of the issued and outstanding stock. The reverse stock split was completed with the state of Florida on March 12, 2020. FINRA's processing was the last step necessary to fully effectuate the reverse split approved by shareholders in October of 2019.